Natural Products Insider is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pilot Therapeutics Receives Patent for GLA Delivery


Pilot Therapeutics Receives Patent for GLA Delivery

WINSTON-SALEM, N.C.--Pilot Therapeutics recently received a patent (No. 6,107,334) from the U.S. Patent and Trademark Office covering its delivery formulation of gamma linolenic acid (GLA) for treating inflammatory disorders.

According to the company, the method delivers both GLA and a delta-5 desaturase inhibitor to minimize GLA's possible increase on serum arachidonic acid. "The patent for our unique formulation of bioactive lipid technologies is a significant milestone in Pilot's development of novel dietary supplements to treat inflammatory and proliferative diseases," said Kenneth Tramposch, Ph.D., executive vice president and chief operating officer. For more information, visit

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.